Syndax Pharmaceuticals (SNDX) Competitors

Syndax Pharmaceuticals (NASDAQ:SNDX) and ADMA Biologics (NASDAQ:ADMA) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their community ranking, dividends, analyst recommendations, institutional ownership, valuation, earnings, profitability, risk and media sentiment.

Is SNDX or ADMA more profitable?

ADMA Biologics has a net margin of 17.80% compared to Syndax Pharmaceuticals' net margin of 0.00%. ADMA Biologics' return on equity of 53.20% beat Syndax Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Syndax Pharmaceuticals	N/A	-64.34%	-57.72%
ADMA Biologics	17.80%	53.20%	26.07%

Does the media favor SNDX or ADMA?

In the previous week, ADMA Biologics had 7 more articles in the media than Syndax Pharmaceuticals. MarketBeat recorded 14 mentions for ADMA Biologics and 7 mentions for Syndax Pharmaceuticals. ADMA Biologics' average media sentiment score of 1.13 beat Syndax Pharmaceuticals' score of 0.36 indicating that ADMA Biologics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Syndax Pharmaceuticals	0 Very Positive mention(s)	2 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
ADMA Biologics	8 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Which has more volatility and risk, SNDX or ADMA?

Syndax Pharmaceuticals has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Comparatively, ADMA Biologics has a beta of 0.6, suggesting that its stock price is 40% less volatile than the S&P 500.

Which has better earnings & valuation, SNDX or ADMA?

ADMA Biologics has higher revenue and earnings than Syndax Pharmaceuticals. Syndax Pharmaceuticals is trading at a lower price-to-earnings ratio than ADMA Biologics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Syndax Pharmaceuticals	$23.68M	49.81	-$209.36M	-$3.73	-3.68
ADMA Biologics	$426.45M	10.98	-$28.24M	$0.82	24.15

Do analysts rate SNDX or ADMA?

Syndax Pharmaceuticals currently has a consensus price target of $36.20, suggesting a potential upside of 164.04%. ADMA Biologics has a consensus price target of $22.50, suggesting a potential upside of 13.64%. Given Syndax Pharmaceuticals' higher probable upside, analysts clearly believe Syndax Pharmaceuticals is more favorable than ADMA Biologics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Syndax Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.90
ADMA Biologics	0 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	3.25

Does the MarketBeat Community prefer SNDX or ADMA?

ADMA Biologics received 23 more outperform votes than Syndax Pharmaceuticals when rated by MarketBeat users. Likewise, 72.13% of users gave ADMA Biologics an outperform vote while only 65.60% of users gave Syndax Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Syndax Pharmaceuticals	Outperform Votes 391 65.60%	Underperform Votes 205 34.40%
ADMA Biologics	Outperform Votes 414 72.13%	Underperform Votes 160 27.87%

Do institutionals and insiders hold more shares of SNDX or ADMA?

75.7% of ADMA Biologics shares are owned by institutional investors. 4.1% of Syndax Pharmaceuticals shares are owned by insiders. Comparatively, 3.7% of ADMA Biologics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

Summary

ADMA Biologics beats Syndax Pharmaceuticals on 14 of the 19 factors compared between the two stocks.